Interested in Connecting? Please contact: Scott Pancoast CEO & Founder firstname.lastname@example.org
Message the company or request a 1:1 meeting here.
Zylö is developing a patented topical drug-delivery technology that enhances bioavailability of a wide variety of actives. We have several signed partnerships that involve seven different actives.
Our two lead programs are: (i) anandamide-loaded Z-pods for the treatment of cutaneous manifestations of lupus; Hoth Therapeutics has the North American rights to the drug candidate, and we are seeking additional partners to develop the drug candidate in Asia, Europe, etc., and (ii) nitric-oxide-loaded Z-pods for a wide array of indications, including burns, otitis media, onychomycosis, and erectile dysfunction (ED); we have received two grants to advance the ED program, and received a strong score recently on our Phase 2 NIH grant application for $1.7 million.